Inmunomet - Microviable Therapeutics S.L.

Microviable Therapeutics announces Research Collaboration with Venter Pharma and Inmunomet Intolerancia y Disbiosis

adminMicroVi2022-07-08T13:12:03+02:008 de July de 2022|

Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]

Microviable announces 1.5 million € investment to advance the company´s microbiota-derived biotherapeutic products.

adminMicroVi2022-04-19T20:48:43+02:0019 de April de 2022|

Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]